We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
S
176
SignatureFD
Georgia
$82.6K -$6.26K -46 -7%
Walleye Capital
177
Walleye Capital
New York
$75.8K +$71.7K +527 +1,817%
Osaic Holdings
178
Osaic Holdings
Arizona
$51.7K -$1.63M -11,946 -97%
QCG
179
Quadrant Capital Group
Ohio
$46.6K +$1.5K +11 +3%
US Bancorp
180
US Bancorp
Minnesota
$42.3K -$816 -6 -2%
GI
181
GAMMA Investing
California
$41.6K +$952 +7 +2%
LC
182
Lindbrook Capital
California
$39.3K -$136 -1 -0.3%
LSA
183
Leonteq Securities AG
Switzerland
$35.9K +$25.2K +185 +237%
EWA
184
EverSource Wealth Advisors
Alabama
$28.6K +$5.31K +39 +22%
Fifth Third Bancorp
185
Fifth Third Bancorp
Ohio
$23.7K – – –
PA
186
Parallel Advisors
California
$21.3K – – –
FFA
187
Farther Finance Advisors
California
$20.8K – – –
CAS
188
Coppell Advisory Solutions
Texas
$20.4K +$19.2K +141 New
Zurich Cantonal Bank
189
Zurich Cantonal Bank
Switzerland
$19K -$408 -3 -2%
BTI
190
Blue Trust Inc
Georgia
$9.98K +$8.98K +66 New
SAM
191
Smartleaf Asset Management
Massachusetts
$9.75K +$1.23K +9 +14%
BIA
192
Bell Investment Advisors
California
$7.09K +$680 +5 +11%
Jones Financial Companies
193
Jones Financial Companies
Missouri
$6.82K +$6.8K +50 New
HCM
194
Hollencrest Capital Management
California
$6.55K +$1.36K +10 +26%
PTC
195
Private Trust Company
Ohio
$5.32K – – –
WTA
196
Washington Trust Advisors
Massachusetts
$5.18K – – –
QC
197
Quent Capital
New York
$5.18K – – –
BWL
198
Bogart Wealth LLC
Virginia
$4.64K – – –
HI
199
Hoey Investments
Pennsylvania
$3.27K – – –
EBA
200
Eagle Bay Advisors
New York
$3.17K – – –
6 7
8
9 10

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.